课题基金 / 基金详情

Development of peptide therapeutics via nasal delivery for major depression disorder

Development of peptide therapeutics via nasal delivery for major depression disorder
通过鼻腔递送治疗重度抑郁症的肽疗法的开发
批准号：
240644
负责人：
Liu Fang
金额：
$10.93万
依托单位：
Centre for Addiction and Mental Health (Toronto)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2011
资助国家：
加拿大
项目状态：
已结题
起止时间：
2011-09-01 至 2012-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=240644&lang=en
关键词：
Dopamine Receptors Major Depression Disorder Peptide Therapeutics Protein-Protein Interaction

项目摘要

项目成果

Liu Fang的其他基金

相似基金

相关文献

中文摘要
翻译
重度抑郁症（MDD）导致显著的发病率和死亡率，并对功能产生深刻的致残影响。在发达国家，MDD导致任何疾病的残疾所造成的生命损失年数最多。以目前的治疗，只有1/3
英文摘要
Major depressive disorder (MDD) causes significant morbidity and mortality, and has profoundly disabling effects on functioning. In the developed world, MDD causes the most years of life lost to disability of any disease. With current treatment, only 1/3
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating a novel pathway regulating dendritic spine pruning in Fmr1 knock out mice
The role of FK506 binding protein 51 in the regulation of glucocorticoid receptor signaling
The role of FK506 binding protein 51 in the regulation of glucocorticoid receptor signaling
Application Development Workshop for the Team Grant: GACD Mental Health - Canada-China program
海外基金